ArticleJournal of controlled release : official journal of the Controlled Release Society2021
Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 85 citations in OpenAlex.
- Repurposing Non-oncologic Drugs via Targeted Nanocarriers for Cancer Therapy: Mechanisms, Synergistic Combinations, and Clinical Translation.AAPS PharmSciTech · 2026Review
- Cytoprotective and Genoprotective Effects of Gelatin-Encapsulated Quercetin Against Oxidative Cell Damage.Molecules (Basel, Switzerland) · 2026Article
- From single DNA molecule to nanoparticle formation: mechanistic basis for monocationic aromatic drug-induced DNA frameworks.Journal of nanobiotechnology · 2026Article
- Emerging Nanomedicine Strategies for Chronic Disease Management Based on Chitosan.International journal of molecular sciences · 2026Review
- A novel nanoparticle glutathione and Lepidium sativum treatment for gentamicin-induced acute renal failure in rats.Scientific reports · 2025Article
- Tankyrase 2 as a therapeutic target in non-small cell lung cancer: Implications for apoptosis and migration.World journal of clinical oncology · 2025Article
- A novel pharmacological strategy using nanoparticles with glutathione and virgin coconut oil to treat gentamicin-induced acute renal failure in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Effect of chitosan on buck semen quality and semen plasma metabolites during low-temperature storage.Frontiers in veterinary science · 2025Article
- Novel Fast-Setting and Mechanically-Strong Calcium Phosphate Pulp-Capping Cement with Metformin Release to Enhance Dental Pulp Stem Cells.Bioengineering (Basel, Switzerland) · 2024Article
- Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Rapamycin-encapsulated nanoparticle delivery in polycystic kidney disease mice.Scientific reports · 2024Article
- Oral delivery of nanomedicine for genetic kidney disease.PNAS nexus · 2024Article
- Functional Chitosan and Its Derivative-Related Drug Delivery Systems for Nano-Therapy: Recent Advances.Pharmaceutics · 2024Review
- Article
- Marine biomaterials in biomedical nano/micro-systems.Journal of nanobiotechnology · 2023Review
- Folate conjugated nanomedicines for selective inhibition of mTOR signaling in polycystic kidneys at clinically relevant doses.Biomaterials · 2023Article
- A sub-10-nm, folic acid-conjugated gold nanoparticle as self-therapeutic treatment of tubulointerstitial fibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Chitosan Derivative-Based Microspheres Loaded with Fibroblast Growth Factor for the Treatment of Diabetes.Polymers · 2023Article
- Targeting the ADPKD methylome using nanoparticle-mediated combination therapy.APL bioengineering · 2023Article
- β-Glucan and Fatty Acid Based Mucoadhesive Carrier for Gastrointestinal Tract Specific Local and Sustained Drug Delivery.Biomolecules · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Nanoparticle drug delivery has many advantages over small molecule therapeutics, including reducing off-target side effects and increasing drug potency. However, many nanoparticles are administered parenterally, which is challenging for chronic diseases such as polycystic kidney disease (PKD), the most common hereditary disease worldwide in which patients need continuous treatment over decades. To address this clinical need, we present the development of nanoparticles synthesized from chitosan, a widely available polymer chosen for its ability to improve oral bioavailability. Specifically, we optimized the synthesis parameters of chitosan nanoparticles and demonstrate mucoadhesion and permeation across an intestinal barrier model in vitro. Furthermore, when administered orally to mice, ex vivo imaging of rhodamine-loaded chitosan nanoparticles showed significantly higher accumulation in the intestines compared to the free model drug, as well as 1.3 times higher serum area under the curve (AUC), demonstrating controlled release and improved serum delivery over 24 h. To test its utility for chronic diseases such as PKD, we loaded the candidate PKD drug, metformin, into chitosan nanoparticles, and upon oral administration to a PKD murine model (Pkd1
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.